Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + cisplatin + fluorouracil + avelumab
- Development stage
- Unknown
- Lead developer
- McGill University Health Centre
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of the immune checkpoint inhibitor avelumab integrated with a modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) chemotherapy regimen. Avelumab is a human IgG1 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing it from binding to PD-1 and B7.1 receptors on T cells, thereby restoring anti-tumor immune responses. The mDCF component provides cytotoxic debulking: docetaxel stabilizes microtubules to inhibit mitosis, cisplatin induces DNA cross-linking to trigger apoptosis, and 5-fluorouracil inhibits thymidylate synthase to disrupt DNA synthesis. This perioperative regimen is primarily being investigated for the treatment of resectable locally advanced esophago-gastric adenocarcinomas to improve pathologic complete response rates and disease-free survival.
- Other names
- mDCF + avelumabmodified DCF + avelumabavelumab plus mDCF
02
Targets
MicrotubuleDNATUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on docetaxel + cisplatin + fluorouracil + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + cisplatin + fluorouracil + avelumab.